InvestorsHub Logo
Followers 466
Posts 26938
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 169

Tuesday, 05/08/2012 5:20:01 PM

Tuesday, May 08, 2012 5:20:01 PM

Post# of 267
4:21PM Jazz Pharma beats by $0.01, beats on revs; guides FY12 EPS below consensus, revs below consensus (JAZZ) 50.37 -0.40 : Reports Q1 (Mar) earnings of $0.91 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus Estimate of $0.90; revenues rose 113.0% year/year to $108.4 mln vs the $102.65 mln consensus. Co issues downside guidance for FY12, sees EPS of $4.25-4.40, excluding non-recurring items, vs. $4.41 Capital IQ Consensus Estimate; sees FY12 revs of $500-510 mln vs. $538.76 mln Capital IQ Consensus Estimate.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent JAZZ News